<scp>ZNF521</scp>/<scp>EBF1</scp> axis regulates <scp>AKR1B1</scp> to promote the proliferation, migration, and invasion of gastric cancer cells

Yu Cheng, Yijiang Ni, Liming TangThe Kaohsiung Journal of Medical Sciences 2022 · DOI

TL;DR

This study uncovers a novel molecular pathway, the ZNF521/EBF1/AKR1B1 axis, that drives the growth, migration, and invasion of gastric cancer cells. By elucidating how ZNF521 promotes cancer progression through EBF1 and AKR1B1, the research identifies potential new therapeutic targets for combating this deadly disease.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant global health challenge, particularly in East Asia, despite declining incidence rates. The underlying mechanisms of GC oncogenesis are still not fully understood, leading to an unmet need for effective novel treatment strategies. This paper aims to shed light on the role of a specific protein, Aldo-keto reductase family 1 member B (AKR1B1), in GC progression and to unravel the molecular network that regulates it.

Methods

The researchers employed a multi-pronged approach to investigate the ZNF521/EBF1/AKR1B1 axis:

  • Cellular Assays: Standard techniques like CCK-8 assays were used to measure cell proliferation, wound healing assays for cell migration, and Transwell assays for cell invasion.
  • Gene Expression Analysis: Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to measure mRNA and protein levels of key genes (AKR1B1, EBF1, ZNF521).
  • Molecular Interaction Studies:
    • Luciferase Reporter Assay: This technique was used to confirm the direct interaction between the transcription factor EBF1 and the promoter region of the AKR1B1 gene.
  • Chromatin Immunoprecipitation (ChIP): ChIP assays were performed to provide further evidence of EBF1 binding to the AKR1B1 promoter.
  • Gene Manipulation: Techniques like shRNA-mediated knockdown and plasmid-based overexpression were used to alter the expression levels of ZNF521, EBF1, and AKR1B1 in GC cell lines.

Datasets

Not discussed in the paper. The study primarily relies on experiments conducted using established human gastric epithelial (GES-1) and gastric cancer cell lines (AGS and NCI-N87).

Key Insights and Ideas

  • AKR1B1 as a Driver of GC Progression: The study firmly establishes that elevated AKR1B1 expression in GC cells directly contributes to increased proliferation, migration, and invasion. This highlights AKR1B1 as a key player in GC aggressiveness.
  • EBF1 as a Tumor Suppressor: In contrast to AKR1B1, EBF1 acts as a negative regulator of AKR1B1. Overexpressing EBF1 suppresses AKR1B1 and, consequently, inhibits GC progression, positioning EBF1 as a potential tumor suppressor.
  • ZNF521 as an Oncogenic Regulator: ZNF521 emerges as an upstream regulator that promotes GC progression. Its knockdown leads to increased EBF1 expression, which in turn downregulates AKR1B1 and attenuates cancer cell growth and invasiveness.
  • The ZNF521/EBF1/AKR1B1 Axis: The core finding is the identification of this novel signaling axis. ZNF521 antagonizes EBF1's repressive effect on AKR1B1, thereby promoting AKR1B1 expression and driving GC progression. This provides a mechanistic link between these three key molecules.

Key Results

  • Elevated AKR1B1 in GC: AKR1B1 expression was significantly higher in GC cell lines (AGS, NCI-N87) compared to normal gastric epithelial cells (GES-1).
  • AKR1B1 Knockdown Inhibits GC: Reducing AKR1B1 levels via shRNA significantly suppressed proliferation, migration, and invasion in GC cells.
  • EBF1 Overexpression Suppresses AKR1B1: Overexpressing EBF1 led to a decrease in both mRNA and protein levels of AKR1B1, and this also inhibited GC cell proliferation, migration, and invasion.
  • ZNF521 Knockdown Upregulates EBF1: Knocking down ZNF521 increased EBF1 expression, which subsequently decreased AKR1B1 levels and attenuated GC progression.
  • AKR1B1 Rescues ZNF521 Knockdown Effects: When ZNF521 was knocked down, the resulting inhibition of GC progression was reversed by overexpressing AKR1B1, confirming AKR1B1's essential role in ZNF521-mediated tumor promotion.

Limitations and Future Work

  • In vivo Studies: While the study provides strong in vitro evidence, the authors do not present in vivo data using animal models. Future work should validate these findings in more complex biological systems.
  • Clinical Correlation: Although the paper mentions that elevated AKR1B1 is correlated with worse outcomes in GC patients, further detailed clinical correlation studies would strengthen the translational relevance of the findings.
  • Therapeutic Target Exploration: The authors suggest that targeting this ZNF521/EBF1/AKR1B1 axis could be a potential strategy for anti-GC treatments. Future research should focus on developing and testing specific inhibitors or modulators of this pathway.
  • Broader Roles of ZNF521 and EBF1: While the study focuses on their roles in the AKR1B1 axis, further investigation into the broader functions and regulatory networks of ZNF521 and EBF1 in GC could reveal additional therapeutic avenues.

Summary updated

Abstract

Although the incidence and death rates of gastric cancer (GC) are decreasing, approximately one million new cases and 800,000 GC-related deaths were reported worldwide in 2018. Currently, the oncogenesis of GC remains unclear, and the demand for novel treatment options are unmet. Here, we explored the role of aldo-keto reductase family 1 member B (AKR1B1) in the progression of GC. The proliferation, migration, and invasion of GC cells were evaluated by CCK-8 assay, wound healing assay, and transwell assay, respectively. The interaction between EBF transcription factor 1 (EBF1) and the promoter region of AKR1B1 was determined by luciferase reporter assay and chromatin immunoprecipitation (ChIP). Gene expression levels were measured by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting assay. The expression of AKR1B1 was elevated in GC cells, resulting in increased cell proliferation, migration, and invasion. Meanwhile, EBF1 was a negative regulator of AKR1B1; its overexpression suppressed AKR1B1 expression and GC progression. Furthermore, knockdown of ZNF521 induced EBF1 expression, thus suppressing AKR1B1 expression and resulting in attenuated GC growth and invasiveness. Notably, knockdown of ZNF521 attenuated GC progression and was rescued by overexpression of AKR1B1. Our current study revealed a novel ZNF521/EBF1/AKR1B1 axis in GC and elaborated its important role in promoting GC progression, providing potential therapeutic targets for anti-GC treatments.
BibTeX
@article{cheng2022scp,
  author = {Yu Cheng and Yijiang Ni and Liming Tang},
  title = {{<scp>ZNF521</scp>/<scp>EBF1</scp> axis regulates <scp>AKR1B1</scp> to promote the proliferation, migration, and invasion of gastric cancer cells}},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2022},
  doi = {10.1002/kjm2.12624},
}
Figure